J.F.R. Robertson

Prognostic markers in triple‐negative breast cancer

Emad A. Rakha, Maysa E. El‐Sayed, Andrew R. Green et al. · Cancer · 2006 · 1.3K citations

Medicine, Oncology, Breast Oncology +16

Anastrozole Versus Tamoxifen as First-Line Therapy for Advanced Breast Cancer in 668 Postmenopausal Women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability Study

Jacques Bonneterre, Beat Thürlimann, J.F.R. Robertson et al. · Journal of Clinical Oncology · 2000 · 840 citations

Medicine, Oncology, Pharmacology +15

Fulvestrant, Formerly ICI 182,780, Is as Effective as Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing After Prior Endocrine Treatment

Anthony Howell, J.F.R. Robertson, J. Albano et al. · Journal of Clinical Oncology · 2002 · 669 citations

Medicine, Oncology, Pharmacology +14

High‐throughput protein expression analysis using tissue microarray technology of a large well‐characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses

Dalia M. Abd El‐Rehim, Graham Ball, Sarah E. Pinder et al. · International Journal of Cancer · 2005 · 612 citations · Full text

Life Sciences, Molecular Biology, Oncology +17

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

J.F.R. Robertson, Ekaterina Trishkina, Mikhail Dvorkin et al. · The Lancet · 2016 · 602 citations · Full text

Medicine, Oncology, Pharmacology +14